Xintela prepares for oncology spinout

#Regulatory

Lund, Sweden, 20th of Mars 2018 - Xintela AB (publ) announces today that the company has decided to prepare for a possible spin-out of its oncology business into a separate company to be distributed to Xintelas existing shareholders through a stock dividend and listed on a suitable stock market during 2018.

Since 2014, Xintela's cancer project focusing on the aggressive brain tumor glioblastoma has developed in parallel with Xintela's stem cell business. The two businesses use the same integrin technology platform and have, in the early development phase, benefited from being under one roof.

As the two businesses continue to progress, a spin-out and separate financing of the oncology business may provide greater opportunity for it to develop and, thereby, realize its true value potential.

“Our oncology project, with a first focus on the treatment of glioblastoma, has developed very well over the years. We have also identified additional opportunities in the oncology field and therefore believe that the time is right to further develop the oncology program in a separate company”, said Xintela’s Chairman of the Board Gregory Batcheller.

Spinning-out the oncology business will allow Xintela to focus on regenerative medicine. By the end of the year Xintela plans to have its GMP manufacturing facility up and running and will be able to start producing stem cells for human and animal clinical studies.

“This is a perfect time for Xintela to put all its focus on the stem cell business. With our unique stem cell technology and our own manufacturing facility, we have created a strong position in the cell therapy field. A stem cell focus for Xintela will also facilitate future partnering deals and at the same time allow the oncology business to focus on activities that will enable it to achieve maximum value for our shareholders,” said Xintelas CEO Evy Lundgren-Åklerlund.

The spin-out is expected to be completed during 2018 and is subject to market, regulatory and certain other conditions, including approval by Xintela’s board of directors. Further updates to the progress of the spin-out and stock market listing process will be provided in a timely manner.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se

For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se

About Xintela
Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury. In addition, Xintela has developed an assay XACTTM for the quality control chondrocyte preprations in cell therapy of cartilage.    XINMARK® is also used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against glioblastoma, the most common and aggressive form of brain tumors in adults. Positive preclinical results from cell studies and animal model have shown that the antibody has a killing effect on glioblastoma cells and thus has confirmed the concept. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 20th of Mars 2018, at 13.00 CET.

Archive

Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

May 20, 2025
May 21, 2025
Biostock, The Global Forum 2025
May 15, 2025
May 16, 2025
13th Oswestry/Keele Cartilage Symposium, Keele (UK)
Apr 15, 2025
Apr 17, 2025
Cell & Gene meeting on the med, Rome (Italy)
Dec 12, 2024
Dec 14, 2024
4th Regenerative Medicine Orthopedic Summit, Miami
Nov 4, 2024
Nov 6, 2024
BIO-Europe, Stockholm, Sweden
Sep 25, 2024
Sep 27, 2024
7th ICRS Summit, Catania
Sep 18, 2024
Sep 20, 2024
EORS 2024, Aalborg
Sep 4, 2024
Sep 6, 2024
ISCT Europe 2024, Gothenburg
Jul 10, 2024
Jul 13, 2024
ISSCR 2024, Hamburg
Jun 3, 2024
Jun 6, 2024
BIO International Convention, San Diego
May 8, 2024
May 10, 2024
21st ESSKA Congress, Milan
Nov 30, 2023
Dec 2, 2023
3rd Regenerative Orthopaedic Summit by the Regenerative Medicine Orthopaedic Society (RMOS), Istanbul
Nov 21, 2023
Nov 23, 2023
43rd Orthopaedic World Congres by the International Society of Orthopaedic Surgery and Traumatology (SICOT), Cairo
Oct 10, 2023
Oct 12, 2023
2023 Cell & Gene Meeting on the Mesa, Carlsbad, October 10-12
Sep 9, 2023
Sep 12, 2023
- 17th world congress by the International Cartilage Regeneration & Joint Preservation Society (ICRS), Sitges/Barcelona
Jun 5, 2023
Jun 8, 2023
BIO International Convention, Boston
May 31, 2023
Jun 3, 2023
23rd European Congress of Rheumatology, by European Alliance of Associations for Rheumatology (EULAR), Milan
May 11, 2023
May 13, 2023
2nd Regenerative Orthopaedic Summit, Naples
May 12, 2023
May 13, 2023
10. Berliner Knorpelsymposium, Berlin
Apr 27, 2023
Apr 29, 2023
ICRS Focus Meeting on Allografts and synthetics on the frontstage, Nice
Apr 12, 2023
Apr 14, 2023
Cell & Gene Meeting on the Med 2023 Barcelona
Mar 17, 2023
Mar 20, 2023
OARSI world congress on osteoarthritis, Denver
Mar 16, 2023
BioStock Investor Meeting (broadcast online)
Mar 1, 2023
Mar 2, 2023
European Life Sciences CEO Forum (ELSF 2023) in Zürich, March 1-2, 2023
Feb 22, 2023
Redeye Theme: Regenerative Medicine / Cell Therapy, February 22, 2023
Jan 9, 2023
JPM Annual Healthcare Meeting 2023, San Francisco, January 9-12
Dec 1, 2022
1st Regenerative Orthopaedic Summit, Athens, December 1-3, 2022
Nov 29, 2022
BioStock Life Science Summit, Lund, November 29-30 2022
Nov 14, 2022
Investival Showcase, London, November 14, 2022
Nov 2, 2022
BioEurope (Digitalt), November 2-4, 2022
Oct 11, 2022
2022 Cell & Gene Meeting on the Mesa, Carlsbad, October 11-13
Oct 6, 2022
ICRS Focus Meeting, Bologna, October 6-7
Sep 28, 2022
Nordic Life Science Days, Malmö, September 28-29, 2022
Aug 30, 2022
2nd Integrin-Targeted Drug Development Summit, Boston, August 30 - September 1
Jun 13, 2022
Småbolagsdagarna, Stockholm, June 13-15
Jun 13, 2022
Bio International Convention, San Diego, June 13-16
June 1, 2023

CEO Evy Lundgren-Åkerlund presents the company at ProHearings Capital Market Day in Stockholm on June 1, 2023.

June 1, 2022

Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).

January 22, 2024
BioStock: Targinta’s CEO “Strong interest in ADCs in 2023”
June 1, 2023
DIs #InvestTalks - Xintela develops new generation stem cell products
May 30, 2023
BioStock: Xintela highlights the unique properties of XSTEM
May 2, 2023
BioStock: Xintela initiates last dose level in knee osteoarthritis study
March 22, 2023
BioStock: Targinta positions itself in the ADC field
July 6, 2022
BioStock: Xintela in clinical development
June 1, 2022
BioStock Studio: Xintela's CEO comments on the upcoming share issue
April 12, 2022
BioStock: Xintela's CEO on the potential in difficult-to-heal wounds
March 4, 2022
BioStock: Xintela presents plans for 2022 in its Q4 report
January 27, 2022
BioStock Studio: Targinta provides business update prior to spin-off
January 19, 2022
BioStock: Xintela advances to clinical phase in osteoarthritis and difficult-to-heal wounds 2022
October 12, 2021
BioStock: Professor Folke Sjöberg about XSTEM for treatment of venous leg ulcers.
November 9, 2020
BioStock: Xintela’s CEO comments on the positive patent notice
June 22, 2017
Xintela covered in GEN regarding its participation in multi-million, government funded initiative to form a...
March 2, 2017
Xintela covered in Horsetalk.co.nz regarding that its stem cells are safe for use in horses
March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
June 4, 2025
Västra Hamnen Corporate Finance has published an analysis of Xintela.
May 12, 2025
Västra Hamnen Corporate Finance has published an analysis of Xintela.
May 12, 2025
Västra Hamnen Corporate Finance has published an analysis of Xintela.
May 2, 2025
Västra Hamnen Corporate Finance has published an analysis of Xintela.
November 29, 2024
Västra Hamnen Corporate Finance has published a research update for Q3 2024.
September 5, 2024
Västra Hamnen Corporate Finance has published a research update for Q2 2024
May 29, 2024
Västra Hamnen Corporate Finance has published a research update Q1 2024
March 13, 2024
Västra Hamnen Corporate Finance has published a research update for Q4 2023.
December 1, 2023
Västra Hamnen Corporate Finance has published an initial analysis of Xintela.
December 10, 2021
Edison Group has published a research update on Xintela.
July 14, 2021
Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter
November 9, 2020
A status report of the Xintela has been published by Biostock
April 12, 2018
Read the full analysis here
Top